# OnCo record nct07286149 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07286149/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07286149", "NCT07286149" ;
  schema:name "A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)"@en ;
  schema:alternateName "KEYMAKER-U01"@en ;
  schema:description "A phase 1/2 trial of Calderasib, Patritumab deruxtecan, Sacituzumab tirumotecan and Cetuximab in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07286149/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07286149> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2026-04-30" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:drugs <https://onco.cc/drugs/calderasib/>, <https://onco.cc/drugs/patritumab-deruxtecan/>, <https://onco.cc/drugs/sacituzumab-tirumotecan/>, <https://onco.cc/drugs/cetuximab/> ;
  onco:companies <https://onco.cc/companies/merck/>, <https://onco.cc/companies/daiichi-sankyo/> .